Analytical Data
-
基因名
FGFR-3 alpha (IIIc)
-
简介
The FGFR-3 protein is a tyrosine-protein kinase receptor for fibroblast growth factor that is critical for cellular processes, particularly in chondrocytes, osteoblasts, and inner ear development. Its effects span normal skeletal development and postnatal bone mineralization. FGFR-3 beta (IIIc) Protein, Human (HEK293, His-Avi) is the recombinant human-derived FGFR-3 beta, expressed by HEK293 , with C-Avi, C-His labeled tag.
- Application
-
别名
ACH; CD333; CEK; CEK2; EC 2.7.10; FGF R3; FGFR3; HSFGFR3EX; JTK4
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P22607-1
-
表达区间
D127-G375
-
蛋白长度
Partial
-
分子量
50-60 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Fibroblast growth factor receptor 3 (FGFR3) is a member of the fibroblast growth factor receptor family, playing a crucial role in cellular processes such as growth, differentiation, and apoptosis. Particularly, the FGFR3 alpha (IIIc) isoform is significant in bone development and homeostasis, and its mutations are associated with various skeletal disorders, including achondroplasia and thanatophoric dysplasia. These conditions arise from abnormal activation of the receptor, leading to disrupted chondrocyte proliferation and function. Understanding the structure and function of FGFR3 alpha (IIIc) is vital for developing targeted therapies. Recombinant FGFR3 alpha (IIIc) proteins are being researched to elucidate their biochemical properties and signaling mechanisms. Advances in this area may offer insights into novel therapeutic strategies, potentially involving the use of FGFR inhibitors or other modulators to correct dysregulated signaling pathways. Moreover, studying the receptor's interactions with ligands and downstream signaling partners using recombinant proteins could pave the way for identifying biomarkers for FGFR3-related diseases and improving treatment outcomes for affected individuals. Overall, the exploration of FGFR3 alpha (IIIc) recombinant proteins is a promising field that holds the potential to enhance our understanding of skeletal pathologies and inform future clinical applications.
